David Taylor Buys Amgen Inc. Shares

House member David Taylor purchases Amgen shares valued between $1,001 and $15,000.

Written by EarningsIQ · Published Jun 15, 2026, 10:02 AM EDT · Updated Jun 16, 2026, 2:02 PM EDT

Key Points

David Taylor, a member of the House, bought Amgen shares valued between $1,001 and $15,000 on June 5, 2026.
Amgen stock trades near $355.2 with a market cap of $191.7 billion and a forward P/E of 15.13.
Analysts have set new price targets for Amgen, with Piper Sandler maintaining a 'buy' rating and a $427 target.

Congressional trading track record

David Taylor vs. the S&P 500

YTD return -1.3% hypothetical

All-time return +5.0% S&P 500 +11.2%

vs. S&P 500 -6.1% behind the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

David Taylor, a member of the U.S. House of Representatives, recently purchased shares of Amgen Inc. (NASDAQ: AMGN). The transaction, reported on June 15, 2026, involved buying shares valued between $1,001 and $15,000. This move adds a political figure to the list of investors in the healthcare giant.

Other Institutional Activity in Amgen

Amgen has seen varying levels of interest from institutional investors. BlackRock, Inc. slightly trimmed its holdings by 295,666 shares, ending with 47,100,472 shares valued at about $16.57 billion. Vanguard Capital Management LLC made a significant addition, acquiring 35,014,232 shares, now holding the same amount worth approximately $12.32 billion. State Street Corp reduced its stake by 42,915 shares, leaving it with 30,548,488 shares valued at $10.75 billion. Meanwhile, Capital World Investors increased its position by 6,190,632 shares, totaling 29,288,343 shares worth about $10.30 billion.

Amgen Stock Snapshot

Shares of Amgen Inc. trade near $355.2. The company has a market capitalization of approximately $191.7 billion. It sports a P/E ratio of 24.68 and a forward P/E of 15.13, indicating expectations of future earnings growth. Amgen's stock has a 52-week low of $267.83 and a high of $391.29. The 50-day moving average is $340.31, while the 200-day moving average is $330.73. The company's beta is 0.416, suggesting lower volatility compared to the broader market.

Recent Earnings

Amgen reported a revenue of $37.22 billion, with a growth rate of 5.8%. The company's earnings per share (EPS) stand at $14.39, and it has a net margin of 20.96%. Return on equity (ROE) is a robust 101.32%. The next earnings report is expected on August 4, 2026.

Dividend

Amgen offers an annual dividend rate of $10.08, yielding 2.84%. The dividend payout ratio is 67.22%, indicating a healthy distribution of profits back to shareholders.

Insider Buying and Selling at Amgen Inc.

Several insiders purchased shares on May 19, 2026. Charles Holley, Ellen Jamison Kullman, Greg Garland, Wanda Austin, Brian Druker, and Tyler Jacks each bought 665 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 10, 2026, Morgan Stanley maintained a 'hold' rating with a $340 price target. Piper Sandler, on May 14, 2026, reaffirmed a 'buy' rating with a target of $427. The consensus rating for Amgen is a 'buy', with a mean target price of $352.5 from 30 analysts.

About Amgen

Amgen Inc., headquartered in Thousand Oaks, California, is a leading biotechnology company in the healthcare sector. It specializes in discovering, developing, manufacturing, and delivering human therapeutics. The company is known for products like Enbrel, Otezla, and Prolia, which treat a range of conditions from arthritis to osteoporosis. With over 31,500 employees, Amgen operates globally and partners with other major firms to expand its product offerings.

Bottom Line

David Taylor's purchase of Amgen shares highlights ongoing interest in this major biotechnology firm. With substantial institutional activity and analyst attention, Amgen remains a significant player in the healthcare market. Remember, the disclosed trades reflect past actions and may not indicate current holdings.